Wietske Kievit

Summary

Affiliation: Radboud University Nijmegen Medical Centre
Country: The Netherlands

Publications

  1. doi request reprint Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009
    Wietske Kievit
    Department of Rheumatic Diseases 470, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Rheumatology (Oxford) 52:1500-8. 2013
  2. pmc Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis
    Wietske Kievit
    Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Arthritis Care Res (Hoboken) 62:842-7. 2010
  3. doi request reprint Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register
    Wietske Kievit
    Department of Rheumatic Diseases 470, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Rheumatology (Oxford) 50:196-203. 2011
  4. pmc The relationship between change in subjective outcome and change in disease: a potential paradox
    Wietske Kievit
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
    Qual Life Res 19:985-94. 2010
  5. doi request reprint Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies
    W Kievit
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, The Netherlands
    Ann Rheum Dis 68:844-9. 2009
  6. doi request reprint The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data
    W Kievit
    Department of Rheumatology 470, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Ann Rheum Dis 67:1229-34. 2008
  7. pmc The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice
    W Kievit
    Department of Rheumatology 470, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Ann Rheum Dis 66:1473-8. 2007
  8. doi request reprint The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis
    Marlies Blom
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, PO Box 9101, H 470, 6500 HB Nijmegen, The Netherlands
    J Rheumatol 36:2171-7. 2009
  9. doi request reprint Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
    Sanne A A van Dartel
    Department of Rheumatology, University Nijmegen Medical Centre, Huispost 470, Postbus 9101, 6500 HB Nijmegen, The Netherlands
    Rheumatology (Oxford) 52:1052-7. 2013
  10. doi request reprint The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
    Yvonne M R de Punder
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Rheumatology (Oxford) 51:1610-7. 2012

Collaborators

Detail Information

Publications27

  1. doi request reprint Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009
    Wietske Kievit
    Department of Rheumatic Diseases 470, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Rheumatology (Oxford) 52:1500-8. 2013
    ..The objective was to analyse the changes in disease activity, function, joint damage and incidence of orthopaedic surgery over a period of 20 years (1989-2009) for patients with RA...
  2. pmc Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis
    Wietske Kievit
    Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Arthritis Care Res (Hoboken) 62:842-7. 2010
    ..Our objective was to determine the influence of specific attributes relative to a validated measure of disease activity (the Disease Activity Score [DAS]) on rheumatologists' decisions to escalate care...
  3. doi request reprint Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register
    Wietske Kievit
    Department of Rheumatic Diseases 470, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Rheumatology (Oxford) 50:196-203. 2011
    ..The objective of this article is to describe drug survival, disease activity, daily functioning, quality of life and adverse events of TNF-blocking agents in daily clinical practice after 5 years of follow-up...
  4. pmc The relationship between change in subjective outcome and change in disease: a potential paradox
    Wietske Kievit
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
    Qual Life Res 19:985-94. 2010
    ..Therefore, if health deteriorates, the former health state will receive a better rating, whereas if it improves, the former health state will receive a worse rating...
  5. doi request reprint Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies
    W Kievit
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, The Netherlands
    Ann Rheum Dis 68:844-9. 2009
    ..The secondary objective was to evaluate alternatives to the present guidelines with regard to the percentage of responders and costs...
  6. doi request reprint The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data
    W Kievit
    Department of Rheumatology 470, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Ann Rheum Dis 67:1229-34. 2008
    ..Aim: to evaluate the effects of adalimumab, etanercept and infliximab on disease activity, functional ability and quality of life and the medication costs in a naturalistic design...
  7. pmc The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice
    W Kievit
    Department of Rheumatology 470, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Ann Rheum Dis 66:1473-8. 2007
    ..Randomised controlled trials (RCTs) evaluating the efficacy of antagonists to tumour necrosis factor alpha (TNFalpha) showed high response percentages in the groups treated with active drugs...
  8. doi request reprint The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis
    Marlies Blom
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, PO Box 9101, H 470, 6500 HB Nijmegen, The Netherlands
    J Rheumatol 36:2171-7. 2009
    ..To investigate whether the reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent influences the effect of a second TNF blocking agent...
  9. doi request reprint Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
    Sanne A A van Dartel
    Department of Rheumatology, University Nijmegen Medical Centre, Huispost 470, Postbus 9101, 6500 HB Nijmegen, The Netherlands
    Rheumatology (Oxford) 52:1052-7. 2013
    ..The objective of this study was to identify which factors are predictive of the increased risk of serious infections in RA patients treated with TNF inhibiting therapy...
  10. doi request reprint The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
    Yvonne M R de Punder
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Rheumatology (Oxford) 51:1610-7. 2012
    ..6 and minimal disease activity (MDA) criteria, and to compare the extent of residual disease activity with disability in RA patients after 6 months of treatment with anti-TNF...
  11. doi request reprint Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective
    Lydia G Schipper
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, Sint Maartenskliniek Nijmegen, Nijmegen, The Netherlands
    Rheumatology (Oxford) 50:1320-30. 2011
    ....
  12. doi request reprint Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
    Sanne A A van Dartel
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Ann Rheum Dis 72:895-900. 2013
    ..Tumour necrosis factor (TNF)-inhibiting therapy increases the risk of serious infections in rheumatoid arthritis (RA). However, it is not clear whether this risk differs between TNF inhibitors...
  13. doi request reprint Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis
    Marlies Blom
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, HB Nijmegen, The Netherlands
    J Rheumatol 38:2355-61. 2011
    ..To compare the effectiveness of a third tumor necrosis factor-α (TNF-α)-blocking agent with rituximab after failure of 2 TNF-blocking agents in patients with rheumatoid arthritis (RA) in daily clinical practice...
  14. doi request reprint Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study
    Aatke van der Maas
    Department of Rheumatology, Sint Maartenskliniek, Hengstdal 3, Postbus 9011, Nijmegen 6500 GM, The Netherlands
    Ann Rheum Dis 71:1849-54. 2012
    ..Therefore, our local treatment protocol includes tapering infliximab dose. This observational study describes the prevalence of successful down-titration in daily clinical practice and its effect on costs and quality of life (QoL)...
  15. pmc Cost effectiveness of a new strategy to identify HNPCC patients
    W Kievit
    Department of Medical Technology, University Medical Centre Nijmegen, 417 Human Genetics, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Gut 54:97-102. 2005
    ..Distinguishing hereditary non-polyposis colorectal cancer (HNPCC) from non-hereditary colorectal cancer (CRC) can increase the life expectancy of HNPCC patients and their close relatives...
  16. doi request reprint Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice
    Juul M P A van den Reek
    Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Dermatolog Treat 24:361-8. 2013
    ..To increase effectiveness of standard adalimumab treatment 40 mg every other week (EOW) for patients with psoriasis, dose escalation to 40 mg every week or addition of methotrexate (MTX) are possible strategies...
  17. pmc Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcome
    Marieke J H Coenen
    Department of Human Genetics, Radboud University Nijmegen Medical Centre, Institute for Genetic and Metabolic Disease IGMD, Nijmegen, The Netherlands
    PLoS ONE 5:e14326. 2010
    ..We investigated if genetic variants in TLR genes are associated with RA and response to tumour necrosis factor blocking (anti-TNF) medication...
  18. doi request reprint Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice
    M Blom
    Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Arthritis Care Res (Hoboken) 62:1335-41. 2010
    ..To describe the frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in the treatment of rheumatoid arthritis (RA) in daily clinical practice...
  19. ncbi request reprint [More hereditary intestinal cancer can be detected if patients with colorectal carcinoma that are selected by the pathologist are examined for microsatellite instability]
    J H F M de Bruin
    Universitair Medisch Centrum St Radboud, Postbus 9IoI, 6500 HB Nijmegen
    Ned Tijdschr Geneeskd 149:1792-8. 2005
    ....
  20. ncbi request reprint Comment on the use of self-reporting instruments to assess patients with rheumatoid arthritis: the longitudinal association between the DAS28 and the VAS general health
    W Kievit
    Department of Medical Technology Assessment, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
    Arthritis Rheum 55:745-50. 2006
    ..The objective was to explore the association (in time) between disease activity and patient perception of general health, disease activity, pain, and functional disability in patients with RA...
  21. doi request reprint Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis
    B J Radovits
    Radboud University Nijmegen Medical Centre, Department of Rheumatology, PO Box 9101, HP 470, Nijmegen 6500 HB, The Netherlands
    Ann Rheum Dis 68:1470-3. 2009
    ..To investigate the influence of age on the effectiveness and tolerance of antitumour necrosis factor alpha (TNFalpha) therapy in rheumatoid arthritis (RA)...
  22. doi request reprint The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis
    E J M Toonen
    Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Ann Rheum Dis 67:1174-7. 2008
    ....
  23. doi request reprint Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice
    Paula P M van Lümig
    Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Am Acad Dermatol 68:57-63. 2013
    ..The method used to account for missing observations for the therapy under analysis has a great influence on the inference of efficacy...
  24. ncbi request reprint Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis
    W Kievit
    Department of Medical Technology Assessment, University Medical Center Nijmegen, Nijmegen, The Netherlands
    Clin Genet 65:308-16. 2004
    ..Therefore, a new strategy is needed for the identification of HNPCC...
  25. doi request reprint Prior colorectal neoplasia is associated with increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease
    Lauranne A A P Derikx
    Inflammatory Bowel Disease Center, Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Gastroenterology 146:119-28.e1. 2014
    ..We aimed to determine the cumulative incidence of pouch neoplasia in patients with IBD and identify risk factors for developing pouch neoplasia...
  26. pmc Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis
    Erik J M Toonen
    Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    PLoS ONE 7:e33199. 2012
    ..Our results confirm that gene expression profiling prior to treatment is a useful tool to predict anti-TNF (non) response...
  27. doi request reprint Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety
    Beáta J Radovits
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Drugs Aging 26:647-64. 2009
    ....